Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis

Xavier M Teitsma; Johannes W G Jacobs; Pascal H P de Jong; Johanna M W Hazes; Angelique E A M Weel; Paco M J Welsing; Attila Pethö-Schramm; Michelle E A Borm; Jacob M van Laar; Johannes W J Bijlsma; Floris P J G Lafeber

doi:10.1136/annrheumdis-2018-213767

Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis

Xavier M Teitsma^*, Johannes W G Jacobs, Pascal H P de Jong, Johanna M W Hazes, Angelique E A M Weel, Paco M J Welsing, Attila Pethö-Schramm, Michelle E A Borm, Jacob M van Laar, Johannes W J Bijlsma, Floris P J G Lafeber

^*Corresponding author for this work

Rheumatology

Research output: Contribution to journal › Article › Academic › peer-review

2 Citations (Scopus)

Original language	English
Pages (from-to)	142-144
Number of pages	3
Journal	Annals of the Rheumatic Diseases
Volume	78
Issue number	1
DOIs	https://doi.org/10.1136/annrheumdis-2018-213767
Publication status	Published - Jan 2019

Bibliographical note

Funding:
The U-Act-Early trial was funded by Roche Nederland BV and the work
within the tREACH trial was supported by an unrestricted grant from Pfizer

Access to Document

10.1136/annrheumdis-2018-213767

http://hdl.handle.net/1765/110205

Cite this

Teitsma, X. M., Jacobs, J. W. G., de Jong, P. H. P., Hazes, J. M. W., Weel, A. E. A. M., Welsing, P. M. J., Pethö-Schramm, A., Borm, M. E. A., van Laar, J. M., Bijlsma, J. W. J., & Lafeber, F. P. J. G. (2019). Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis. Annals of the Rheumatic Diseases, 78(1), 142-144. https://doi.org/10.1136/annrheumdis-2018-213767

@article{ebe8ae73f10247489ece4cbb4816ab14,

title = "Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis",

author = "Teitsma, {Xavier M} and Jacobs, {Johannes W G} and {de Jong}, {Pascal H P} and Hazes, {Johanna M W} and Weel, {Angelique E A M} and Welsing, {Paco M J} and Attila Peth{\"o}-Schramm and Borm, {Michelle E A} and {van Laar}, {Jacob M} and Bijlsma, {Johannes W J} and Lafeber, {Floris P J G}",

note = "Funding: The U-Act-Early trial was funded by Roche Nederland BV and the work within the tREACH trial was supported by an unrestricted grant from Pfizer",

year = "2019",

month = jan,

doi = "10.1136/annrheumdis-2018-213767",

language = "English",

volume = "78",

pages = "142--144",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

number = "1",

}

Teitsma, XM, Jacobs, JWG, de Jong, PHP, Hazes, JMW, Weel, AEAM, Welsing, PMJ, Pethö-Schramm, A, Borm, MEA, van Laar, JM, Bijlsma, JWJ & Lafeber, FPJG 2019, 'Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis', Annals of the Rheumatic Diseases, vol. 78, no. 1, pp. 142-144. https://doi.org/10.1136/annrheumdis-2018-213767

Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis. / Teitsma, Xavier M; Jacobs, Johannes W G; de Jong, Pascal H P et al.
In: Annals of the Rheumatic Diseases, Vol. 78, No. 1, 01.2019, p. 142-144.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis

AU - Teitsma, Xavier M

AU - Jacobs, Johannes W G

AU - de Jong, Pascal H P

AU - Hazes, Johanna M W

AU - Weel, Angelique E A M

AU - Welsing, Paco M J

AU - Pethö-Schramm, Attila

AU - Borm, Michelle E A

AU - van Laar, Jacob M

AU - Bijlsma, Johannes W J

AU - Lafeber, Floris P J G

N1 - Funding: The U-Act-Early trial was funded by Roche Nederland BV and the work within the tREACH trial was supported by an unrestricted grant from Pfizer

PY - 2019/1

Y1 - 2019/1

U2 - 10.1136/annrheumdis-2018-213767

DO - 10.1136/annrheumdis-2018-213767

M3 - Article

C2 - 30158123

SN - 0003-4967

VL - 78

SP - 142

EP - 144

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 1

ER -